Ekta Patel

Ekta Patel

Company: Xilio Therapeutics Inc.

Job title: Director - Translational Biomarkers

Seminars:

XTX301, a half-life extended, tumor-selective IL-12, exerts potent anti-tumor activity in mice and has the potential to widen the therapeutic index of IL-12 treatment. 11:30 am

mXTX301 potently inhibits tumor growth in a syngeneic mouse model. XTX301 is well-tolerated in a repeat dose non-GLP non-human primate study. XTX301 may exert potent anti-tumor activity while widening the potential therapeutic index of IL-12 treatment.Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.